Page No.: 2

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound represented by Formula (I):

$$\begin{array}{c|c}
 & & & & & & \\
\hline
 & & & & & \\
\hline
 & & & & & \\
\hline
 & & & & & \\
\hline
 & & & & \\$$

$$\begin{array}{c|c}
 & X^1 \\
 & X^2 \\
 & X^6 \\
 & X^4
\end{array}$$
(I)

or a pharmaceutically acceptable salt thereof, wherein X^1 , X^2 , X^4 , and X^6 are independently C, N, S or O; X^3 is C; and X^5 is are independently C or N; wherein at least one of X^1 , X^2 , X^3 , X^4 , X^5 , and X^6 is N; at most one of X^1 , X^2 , X^4 , and X^6 is S or O; Y is C0 4alkyl, aryl, or heteroaryl; R^1 and R^2 are independently halogen, $C_{0.4}$ alkyl, or pyridyl; and n^1 and n^2 are independently 0 or 1.

- 2. (cancelled)
- 3. (currently amended) The compound according to Claim 21, or a pharmaceutically acceptable salt thereof, wherein X^1 , X^2 , X^3 , X^4 , and X^6 are C.

Page No.: 3

4. (currently amended) The compound according to Claim $2 \underline{1}$, or a pharmaceutically acceptable salt thereof, wherein one of X^2, X^3 and X^4 is N, the other is remaining are C; and X^1 and X^6 are C.

- 5. (currently amended) The compound according to Claim 2 $\underline{1}$, or a pharmaceutically acceptable salt thereof, wherein two of X^2 , X^3 and X^4 are N, the remaining is C; and X^1 and X^6 are C.
- 6. (currently amended) The compound according to Claim 2 $\underline{1}$, or a pharmaceutically acceptable salt thereof, wherein one of X^2 , X^3 and X^4 is N, the other is remaining are C; X^1 is S; and X^6 is C.
- 7. (currently amended) The compound according to Claim 2 1, or a pharmaceutically acceptable salt thereof, wherein one of X^2 , X^3 and X^4 is N, the other is remaining are C; X^1 is S; and X^6 is N.
 - 8. (cancelled)
 - 9. (cancelled)
 - 10. (cancelled)
 - 11. (currently amended) A compound represented by

Page No.: 4

or a pharmaceutically acceptable salt thereof.

12. (previously presented)A pharmaceutical composition comprising: a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

Page No.: 5

- 13. (cancelled)
- 14. (cancelled)
- 15. (currently amended) A method of treatment or prevention of pain comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
- 16. (currently amended) A method of treatment or prevention of a pain disorder wherein said pain disorder is acute pain, persistent pain, chronic pain, inflammatory pain, or neuropathic pain, comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
 - 17. (cancelled)
 - 18. (cancelled)
 - 19. (cancelled)
 - 20. (cancelled)
 - 21. (cancelled)
- 22. (currently amended) A method of treatment or prevention of neuropathic pain comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
 - 23. (cancelled)
 - 24. (cancelled)
 - 25. (cancelled)
- 26. (currently amended) A method of treatment or prevention of inflammatory pain comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
 - 27. (cancelled)
 - 28. (cancelled)
- 29. (new) The compound of claim 1, optionally substituted with a substituent selected from halogen, C0-6alkyl, or heteroaryl.